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Background: The aim of this study was to evaluate clinical outcomes in coronavirus disease 2019 (COVID-19) positive patients 
with type 2 diabetes compared to those without diabetes in Korea.
Methods: We extracted claims data for patients diagnosed with COVID-19 from the National Health Insurance Service database in 
Korea from January 20, 2020 to March 31, 2020. We followed up this cohort until death from COVID-19 or discharge from hospital. 
Results: A total of 5,473 patients diagnosed with COVID-19 were analyzed, including 495 with type 2 diabetes and 4,978 without di-
abetes. Patients with type 2 diabetes were more likely to be treated in the intensive care unit (ICU) (P<0.0001). The incidence of in-
hospital mortality was higher in patients with type 2 diabetes (P<0.0001). After adjustment for age, sex, insurance status, and comor-
bidities, odds of ICU admission (adjusted odds ratio [OR], 1.59; 95% confidence interval [CI], 1.02 to 2.49; P=0.0416) and in-hospi-
tal mortality (adjusted OR, 1.90; 95% CI, 1.13 to 3.21; P=0.0161) among patients with COVID-19 infection were significantly high-
er in those with type 2 diabetes. However, there was no significant difference between patients with and without type 2 diabetes in 
ventilator, oxygen therapy, antibiotics, antiviral drugs, antipyretics, and the incidence of pneumonia after adjustment.
Conclusion: COVID-19 positive patients with type 2 diabetes had poorer clinical outcomes with higher risk of ICU admission and 
in-hospital mortality than those without diabetes. Therefore, medical providers need to consider this more serious clinical course 
when planning and delivering care to type 2 diabetes patients with COVID-19 infection.
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INTRODUCTION
There is currently a global struggle to contain an outbreak of 
coronavirus disease 2019 (COVID-19), caused by severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2). In March 
2020, the World Health Organization declared COVID-19 a 
pandemic. As of July 22, 2020, more than 14.8 million persons 
have been diagnosed with COVID-19 in the world, with more 
than 610,000 deaths. In Korea, the first confirmed case of CO-
VID-19 occurred on January 20, 2020. Korea had globally the 
second largest number of patients with COVID-19 in the early 
days of the outbreak until March 2020. 
Presence of co-morbid conditions have been reported more 
frequently in patients who died with COVID-19 infection. In 
Korea, 96.8% of COVID-19 positive patients who died had un-
derlying diseases and 36.5% had diabetes [1]. According to 
Yang et al. [2], 22% of persons who died of COVID-19 in Wu-
han Jinyintan Hospital had diabetes. In a multi-center observa-
tional study of 1,082 COVID-19 positive patients in Daegu, 
Korea, those with diabetes also exhibited higher mortality [3].
Type 2 diabetes is one of the most prevalent chronic diseases 
worldwide. In 2018, its prevalence in the United States was 
over 10% and it exceeded 25% in the elderly [4]. In Europe, the 
prevalence of type 2 diabetes is close to 10% [5]. In 2008, the 
prevalence of type 2 diabetes was 14.4% in Korea, with 29.8% 
of the elderly population affected, and its prevalence has contin-
ued to increase [6]. 
Studies about the association between COVID-19 and type 2 
diabetes has been reported from around the world. However, 
there are only a few large-scale national studies of the clinical 
course of COVID-19 positive patients with type 2 diabetes in 
Asia, including Korea. Therefore, the purpose of this study was 
to investigate clinical outcomes in COVID-19 positive patients 
with type 2 diabetes compared to those without diabetes in a na-
tional data in Korea. 
METHODS
Data source
In this study, we used National Health Insurance (NHI) claims 
data from the Health Insurance Review & Assessment Service 
(HIRA) that is a government-affiliated agency which supervises 
all medical services in Korea under the Ministry of Health and 
Welfare [7]. This database is maintained by the National Health 
Insurance System (NHIS). The NHIS is the only public medical 
insurance system in Korea and represents the entire Korean 
population, because of the compulsory social insurance system. 
All clinics and hospitals in Korea submit inpatient and outpa-
tient data, including information on the diagnosis and medical 
costs, to the NHIS to claim payments for patient care [7]. People 
who are not included in NHIS due to the lowest income bracket 
are covered by tax-funded programs, including Medicaid.
The database consists of the following four categories: gener-
al information on specifications; consultation statements; diag-
nosis statements based on the International Classification of 
Diseases, 10th revision (ICD-10) guidelines; and detailed infor-
mation about prescriptions [7]. The NHIS contains information 
on patient demographics, medical use/transactions, deductions 
and claims, and insurers’ payment coverage [8]. We extracted 
information for each individual including age, gender, diagno-
sis, prescribed drugs, and pharmacy expenditure, using an un-
identifiable code. The protocol was reviewed and approved by 
the Institutional Review Board of the National Health Insurance 
Service Ilsan Hospital (NHIMC 2020-03-084). The requirement 
for informed consent was waived by the board. 
Operational diagnosis of type 2 diabetes and anti-diabetic 
medications
Retrospective data for patients with type 2 diabetes were ex-
tracted from January 2019 to December 2019. Individuals were 
considered to have type 2 diabetes if anti-diabetic drugs were 
prescribed with the presence of ICD-10 codes E11, E12, E13, or 
E14, as either a principal diagnosis or the 1st to 4th additional 
diagnosis at least once a year [8]. Antidiabetic drugs dispensed 
by the pharmacy during the study period and identified in 
claims records consisted of nine classes (i.e., insulin; biguanide; 
sulfonylurea; thiazolidinedione; dipeptidyl peptidase-4 inhibitor 
[DPP-4i]; sodium-glucose cotransporter 2 inhibitor; meglitinide, 
alpha-glucosidase inhibitor; and glucagon-like peptide-1 ago-
nists) [9]. Patients with type 1 diabetes, defined by three or 
more insulin prescriptions with the presence of an E10 ICD-10 
code, were excluded [10]. 
Detection of COVID-19 cases and deaths
We identified COVID-19 cases based on information from the 
Korea Center for Disease Control & Prevention. COVID-19 di-
agnoses were made between January 20, 2020 and March 31, 
2020. After 10 cases were excluded due to missing date, 5,473 
patietns diagnosed with COVID-19 were analyzed during study 
period. We followed up the cases until their death from COV-
ID-19 or their discharge from hospital. 
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Covariates and clinical care outcomes
Covariates were selected based on the available variables which 
HIRA provided. Age groups were categorized using 10-year in-
tervals. Insurance types were analyzed in terms of NHI and 
medical aid, which reflect economic status, because the insur-
ers’ payments are subdivided by the patient’s economic status as 
described above. Comorbidities were categorized into 14 class-
es and were determined based on ICD-10 codes [11]. We evalu-
ated treatment variables including intensive care unit (ICU) ad-
mission, ventilator, oxygen therapy, antibiotics, antiviral drugs, 
and antipyretics. To evaluate clinical care outcomes, the inci-
dence of pneumonia and in-hospital mortality were analyzed.
Statistical analysis
We used chi-square test to analyze numerical and frequency 
data. Odds ratios (ORs) and 95% confidence intervals (CIs) be-
tween the two groups of interest were calculated using multiple 
logistic regression, with adjustment for age, sex, insurance status, 
and comorbidities. Subgroup analysis was conducted to investi-
gate the association between diabetes and in-hospital mortality 
by age groups. A P<0.05 was considered to indicate a statistical-
ly significant result. All analyses were performed using SAS sta-
tistical software version 9.4 (SAS Institute, Cary, NC, USA). 
RESULTS
Baseline characteristics of the study population 
This study consisted of 5,473 patients diagnosed with COV-
ID-19, including 495 patients with type 2 diabetes and 4,978 
patients without type 2 diabetes. Their demographic data, in-
cluding age, sex, insurance type, and antidiabetic drug usage, 
are presented in Table 1. Patients with type 2 diabetes tended to 
be older (34.5% vs. 8.2% aged ≥70 years) and male (56.4% vs. 
43.4%, P<0.0001). The percentage of persons accessing medi-
cal aid was greater in the type 2 diabetes group. Of the patients 
with type 2 diabetes, 18.6% were using insulin, while metfor-
min and DPP-4i were the most prevalent oral hypoglycemic 
agents (OHAs) (49.1% and 34.9%, respectively; P<0.0001).
Comorbidities, treatments, and outcomes of COVID-19 
positive patients with or without type 2 diabetes
Hypertension (63.8%), pulmonary disease (34.6%), renal dis-
ease (21.8%), cerebrovascular disease (21.4%), and myocardial 
infarction (17.0%) were the most common comorbidities in pa-
tients with type 2 diabetes (Table 1). In those without type 2 dia-
betes, pulmonary disease (28.1%), hypertension (15.0%), and 
asthma (9.8%) were the most common comorbidities. The fre-
quencies of all other comorbidities, except connective tissue 
disease, were significantly higher in patients with type 2 diabe-
tes (P<0.0001, except Asthma P=0.0336 and pulmonary dis-
ease P=0.0028). Patients with type 2 diabetes were more likely 
to be treated in the ICU and require oxygen therapy (P<0.0001) 
and a ventilator (P=0.0025). They were also more likely to be 
treated with antibiotics, antiviral drugs (P<0.0001), and anti-
pyretics (P=0.0311) than patients without type 2 diabetes. The 
incidence of pneumonia (13.1% vs. 7.1%) and in-hospital mor-
tality (5.7% vs. 1.1%) were significantly higher in patients with 
type 2 diabetes (P<0.0001). As a result of classifying COV-
ID-19 positive patients with type 2 diabetes according to antidi-
abetic drugs (Supplemental Table S1), there was no significant 
difference between patients with OHAs and insulin±OHAs in 
variables including outcomes, except for hypertension, myocar-
dial infarction, renal diseases, antiviral, and antipyretics. 
Multivariate analysis of treatments and outcomes of 
COVID-19 positive patients with type 2 diabetes
After adjusting for age, sex, insurance type, and comorbidities, 
there was significantly higher ICU admission frequency in CO-
VID-19 positive patients with type 2 diabetes (adjusted OR, 
1.59; 95% CI, 1.01 to 2.49; P=0.0416) (Table 2). The in-hospi-
tal mortality rate was also higher for those with type 2 diabetes 
(adjusted OR, 1.90; 95% CI, 1.13 to 3.21; P=0.0161). Howev-
er, there were no significant differences in other outcomes be-
tween those with and without type 2 diabetes. Additionally, we 
analyzed whether antidiabetic drugs affected treatment and out-
come variables (Supplemental Table S2). After adjustment for 
age, sex, insurance type, and comorbidities, antidiabetic drugs 
including metformin and DPP-4i were not associated with treat-
ment and outcome variables in COVID-19 patients with type 2 
diabetes. 
Table 3 shows the frequency of in-hospital mortality by age in 
COVID-19 positive patients with and without type 2 diabetes. 
In the age range of 60 to 69 years, the in-hospital mortality rate 
was significantly higher in patients with type 2 diabetes com-
pared to patients without diabetes (P=0.0074). After adjusting 
for sex, insurance status, and comorbidities, patients with type 2 
diabetes had a significantly higher in-hospital mortality rate (ad-
justed OR, 7.83; 95% CI, 1.76 to 34.77; P=0.0068) in the age 
range of 60 to 69 years (Supplemental Table S3). Those in the 
age range of ≥70 years also showed a higher OR of in-hospital 
mortality, but this difference was not statistically significant. 
Adjusted ORs for other treatment and outcome variables by age 
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Total No diabetes Type 2 diabetes
Total 5,473 (100.0) 4,978 (91.0) 495 (9.0) 
Sex <0.0001
   Male 2,439 (44.6) 2,160 (43.4) 279 (56.4) 
   Female 3,034 (55.4) 2,818 (56.6) 216 (43.6) 
Age group, yr <0.0001
   <20 421 (7.7) 419 (8.4) 2 (0.4) 
   20–29 1,269 (23.2) 1,261 (25.3) 8 (1.6) 
   30–39 970 (17.7) 956 (19.2) 14 (2.8) 
   40–49 857 (15.7) 792 (15.9) 65 (13.1) 
   50–59 807 (14.8) 708 (14.2) 99 (20.0) 
   60–69 569 (10.4) 433 (8.7) 136 (27.5) 
   ≥70 580 (10.6) 409 (8.2) 171 (34.5) 
Insurance type <0.0001
   National Health Insurance 5,179 (94.6) 4,756 (95.5) 423 (85.5) 
   Medical aids 294 (5.4) 222 (4.5) 72 (14.5) 
Antidiabetic drugs 
   Insulin - - 92 (18.6) 
   OHAs - -
      Metformin - - 243 (49.1) 
      SU - - 73 (14.7) 
      TZD - - 13 (2.6) 
      DPP-4i - - 173 (34.9) 
      SGLT2i - - 15 (3.0) 
      Meglitinide - - 5 (1.0) 
      AGI - - 2 (0.4) 
   GLP-1 - - 0
Comorbidities 
   Hypertension 1,064 (19.4) 748 (15.0) 316 (63.8) <0.0001
   Myocardial infarction 226 (4.1) 142 (2.9) 84 (17.0) <0.0001
   Heart failure 111 (2.0) 72 (1.5) 39 (7.9) <0.0001
   Peripheral artery diseases  177 (3.2) 143 (2.9) 34 (6.9) <0.0001
   Cerebrovascular diseases 332 (6.1) 226 (4.5) 106 (21.4) <0.0001
   Dementia 141 (2.6) 103 (2.1) 38 (7.7) <0.0001
   COPD 91 (1.7) 71 (1.4)  20 (4.0) <0.0001
   Asthma 552 (10.1) 488 (9.8) 64 (12.9) 0.0336
   Connective tissue diseases 99 (1.8) 92 (1.9) 7 (1.4) 0.6071
   Pulmonary diseases 1,568 (28.7) 1,397 (28.1) 171 (34.6) 0.0028
   Liver diseases 44 (0.8) 30 (0.6) 14 (2.8) <0.0001
   Hemiplegia 41 (0.8) 23 (0.5) 18 (3.6) <0.0001
   Renal diseases 260 (4.8) 152 (3.1) 108 (21.8) <0.0001
   Cancer 366 (6.7) 298 (6.0) 68 (13.7) <0.0001
(Continued to the next page)
COVID-19 and Type 2 Diabetes in Korea
Copyright © 2020 Korean Endocrine Society www.e-enm.org 905
Table 1. Continued
group showed no statistically significant differences (data not 
shown).
DISCUSSION
This nationwide study based on claims data investigated the as-
sociation between COVID-19 and type 2 diabetes in Korea. 
ICU admission and in-hospital mortality rates were significantly 
higher in COVID-19 positive patients with type 2 diabetes. Our 
results confirmed that type 2 diabetes was associated with an in-
creased risk of severity in Korean COVID-19 positive patients.
Type 2 diabetes is known to be a risk factor for morbidity and 
mortality in patients with infections, including pneumonia [12]. 
In a population-based cohort study, Kornum et al. [13] reported 
that type 2 diabetes and high glucose levels on admission were 




Total No diabetes Type 2 diabetes
Treatments 
   Ventilator 34 (0.6) 25 (0.5) 9 (1.8) 0.0025
   Oxygen therapy 276 (5.0) 208 (4.2) 68 (13.7) <0.0001
   Antibiotics 439 (8.0) 360 (7.2) 79 (16.0) <0.0001
   Antiviral drugs 846 (15.5) 726 (14.6) 120 (24.2) <0.0001
   Antipyretics 1,190 (21.7) 1,063 (21.4) 127 (25.7) 0.0311
Outcomes 
   ICU admission 154 (2.8) 121 (2.4) 33 (6.7) <0.0001
   Pneumonia 417 (7.6) 352 (7.1) 65 (13.1) <0.0001
   In-hospital mortality 84 (1.5) 56 (1.1) 28 (5.7) <0.0001
OHA, oral hypoglycemic agent; SU, sulfonylurea; TZD, thiazolidinedione; DPP-4i, dipeptidyl peptidase 4 inhibitor; SGLT2i, sodium-glucose cotrans-
porter 2 inhibitor; AGI, alpha-glucosidase inhibitor; GLP-1, glucagon-like peptide-1 agonist; COPD, chronic obstruction pulmonary disease; ICU, inten-
sive care unit.
Table 2. Adjusted ORs of Treatment and Outcome Variables in 
Coronavirus Disease 2019 Positive Patients with Type 2 Diabe-




Adjusted OR 95% CI
Treatments
   Ventilator 1.00 1.16 0.5–2.65 0.7339 
   O xygen therapy 1.00 1.37 0.99–1.89 0.0597 
   Antibiotics 1.00 1.26 0.94–1.7 0.1228 
   Antiviral drugs 1.00 1.15 0.89–1.48 0.2753 
   Antipyretics 1.00 1.11 0.87–1.41 0.4139 
Outcomes
   ICU admission 1.00 1.59 1.02–2.49 0.0416 
   Pneumonia 1.00 1.16 0.85–1.59 0.3467 
   In-hospital mortality 1.00 1.90 1.13–3.21 0.0161 
The comparisons were made using subjects without diabetes as the ref-
erence group. The ORs were adjusted for age, sex, insurance type, co-
morbidities (hypertension, myocardial infarction, heart failure, periph-
eral disease, cerebrovascular disease, dementia, chronic obstruction 
pulmonary disease, connective tissue disease, pulmonary disease, liver 
disease, hemiplegia, renal diseases, and cancer).
OR, odds ratio; CI, confidence interval; ICU, intensive care unit.
Table 3. Frequency of In-Hospital Mortality by Age in Corona-


















   <20 0 0 0 0 -
   20–29 1 0.788 0 0 1.0000
   30–39 0 0 0 0 -
   40–49 2 2.525 0 0 1.0000
   50–59 12 16.949 1 10.101 1.0000
   60–69 3 6.926 6 44.118 0.0074
   ≥70 38 92.910 21 122.807 0.2930
Total 56 28
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Another population-based case-control study showed that type 
2 diabetes and poor glycemic control were risk factors for pneu-
monia-related hospitalization [14]. Type 2 diabetes has also 
been an important risk factor in previously reported viral infec-
tions. During the 2009 influenza A (H1N1) pandemic, patients 
with type 2 diabetes had a three-fold increased risk of hospital-
ization and a four-fold increased risk of ICU admission [15]. In 
patients with SARS-CoV, type 2 diabetes was a risk factor and 
an independent predictor of mortality and morbidity [16]. Pa-
tients with type 2 diabetes also had a 2.8-fold higher risk of 
mortality after infection with the Middle East respiratory syn-
drome-related coronavirus (MERS-CoV) [17]. Our findings of 
high risk of both ICU care and in-hospital mortality are consis-
tent with the past findings from research on other coronavirus 
outbreaks.
Type 2 diabetes causes the dysregulation of immune mecha-
nisms. A preclinical study showed that the inflammatory re-
sponse of the lungs was slower in mice with diabetes than in 
normal mice, and the reaction time in response to MERS-CoV 
infection was longer [18]. Mice with diabetes were shown to 
have relatively lower levels of inflammatory cytokines and few-
er leukocytes. Other clinical studies also demonstrated that 
components of the host defense system were impaired in pa-
tients with type 2 diabetes, especially the innate immune system 
and leukocytes [19,20]. Hyperglycemia itself has harmful ef-
fects by impairing components of the immune system, such as 
the chemotaxis and phagocytosis of leukocytes [21,22]. Stress 
hyperglycemia increases cytokine production and mortality in 
septic conditions [23]. In addition, antioxidant systems involved 
in bactericidal activity can be impaired in patients with type 2 
diabetes [24]. It is estimated that these host response impair-
ments in diabetes would lead to high levels of morbidity and 
mortality with serious infections such as COVID-19. 
Previous studies on COVID-19 support our findings that ICU 
admission and in-hospital mortality rates were higher in patients 
with type 2 diabetes. A study of 174 Chinese COVID-19 posi-
tive patients reported that patients with diabetes who had no 
other comorbidities had higher mortality rates (16.7% vs. 0%, 
P=0.03) [25]. The same study showed that there was a release 
of tissue injury-related enzymes, uncontrolled inflammation re-
sponses, and a hypercoagulable state in patients with diabetes. 
Another study demonstrated, using a univariate analysis, that 
the OR of in-hospital death was higher in patients with diabetes 
(OR, 2.85; 95% CI, 1.35 to 6.05; P=0.0062) [26]. Guan et al. 
[27] also reported that more patients with diabetes died (10.0% 
vs. 2.5%), and were admitted to the ICU (14.6% vs. 5.5%) com-
pared with those without diabetes in a nationwide analysis in 
China that included about one-third as many patients as includ-
ed in our analyses. The hazard ratio of diabetes was 1.586 in the 
same study (95% CI, 1.03 to 2.45; P=0.037).
This study did not show associations between antidiabetic 
drugs and clinical outcomes in COVID-19 positive patients 
with type 2 diabetes. Previous studies reported that metformin 
treatment was associated with reduced mortality in COVID-19 
patients with type 2 diabetes [28,29]. Metformin is known to 
have the anti-inflammatory properties that may influence the 
clinical outcomes in COVID-19 infection. Other previous stud-
ies reported that coronaviruses, SARS-CoV and MERS-CoV, 
entered the cells by binding to DPP-4 enzyme [30,31]. It has 
been speculated that DPP-4i may be associated with COVID-19 
infection. Further research is necessary to clarify the relation-
ship between antidiabetic drugs and COVID-19. 
The present study had some limitations that should be ad-
dressed in further investigations. Firstly, the data analyzed in 
our study were based on NHI claims. Clinical information, such 
as the state of blood glucose control in patients with type 2 dia-
betes, was not available. In addition, potential confounding 
variables such as smoking and obesity status were also not 
available. Secondly, this study was not able to consider the du-
ration of type 2 diabetes and treatment, because the data ana-
lyzed were from January 2019. Thirdly, we were unable to as-
sess the association between COVID-19 and type 1 diabetes, 
since there were no COVID-19 positive patients with type 1 di-
abetes in our data set. Additionally, date of death was not pro-
vided by HIRA due to the possibility of tracking patients. 
Therefore, survival time could not be calculated.
The strength of our study is that it is a nationwide analysis of 
COVID-19 positive patients in Korea. This study is also the first 
to evaluate COVID-19 outcomes in Korean people with type 2 
diabetes, compared to those without diabetes. Our population 
included a considerable number of younger people without oth-
er comorbidities due to an outbreak of COVID-19 in a specific 
Korean religious group having many young members especially 
between ages 20 to 29 years. Only one death occurred in pa-
tients under age 40 years, and no deaths in these younger per-
sons with diabetes, although the number with this condition was 
small.
In conclusion, COVID-19 positive patients with type 2 diabe-
tes showed poorer clinical outcomes such as higher risk of ICU 
admission and in-hospital mortality than those without diabetes. 
Therefore, medical providers need to consider this more serious 
clinical course when planning and delivering care to type 2 dia-
COVID-19 and Type 2 Diabetes in Korea
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betes patients with COVID-19 infection. Further studies are 
needed to evaluate the mechanism whereby type 2 diabetes 
negatively impacts outcomes in COVID-19.
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